Zydus Lifesciences has agreed to acquire Assertio Holdings for $166.40 million, a move aimed at strengthening its position in the U.S. specialty oncology market. The acquisition includes Assertio’s cancer treatment Rolvedon and adds a commercial network that Zydus expects to use to expand and accelerate its oncology initiatives.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
